N-acetylsulfamethazine is a sulfonamide antibiotic that is produced by the acetylation of sulfamethazine. It is used to treat bacterial infections in animals, and it is also used in some human medications. The compound is typically synthesized by reacting sulfamethazine with acetic anhydride in the presence of a catalyst such as pyridine. N-acetylsulfamethazine is a broad-spectrum antibiotic that is effective against a wide range of bacteria. It is commonly used to treat respiratory infections, urinary tract infections, and skin infections. However, N-acetylsulfamethazine is a relatively old drug and is often replaced by newer, more effective antibiotics. It is studied due to its potential use in developing new drugs for treating multidrug-resistant bacteria. It is also studied for its potential use in the treatment of inflammatory bowel disease. However, it is important to note that the use of N-acetylsulfamethazine is limited by its potential for adverse effects, such as allergic reactions and blood dyscrasias. Further research is ongoing to develop safe and effective N-acetylsulfamethazine-based treatments.'
| ID Source | ID |
|---|---|
| PubMed CID | 108015 |
| MeSH ID | M0101739 |
| Synonym |
|---|
| n-acetyl-n-(p-aminobenzene-sulfonyl)-2-amino-4,6-dimethylpyrimidine |
| acetylsulfadimidine |
| 35255-37-9 |
| n-((4-aminophenyl)sulfonyl)-n-(4,6-dimethyl-2-pyrimidinyl)acetamide |
| acetamide, n-((4-aminophenyl)sulfonyl)-n-(4,6-dimethyl-2-pyrimidinyl)- |
| n-acetylsulfadimidine |
| n-acetylsulfamethazine |
| DTXSID00188751 |
| n-((4-aminophenyl)sulfonyl)-n-(4,6-dimethylpyrimidin-2-yl)acetamide |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of SDM administered in a drench was 88." | ( Pharmacokinetics, renal clearance, tissue distribution, and residue aspects of sulphadimidine and its N4-acetyl metabolite in pigs. Baakman, M; Driessens, F; Mevius, DJ; Nouws, JF; Vellenga, L; Vree, TB, 1986) | 0.27 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacokinetics and tissue distribution experiments were conducted in pigs to which sulphadimidine (SDM) was administered intravenously, orally, and intramuscularly at a dosage of 20 mg SDM/kg." | ( Pharmacokinetics, renal clearance, tissue distribution, and residue aspects of sulphadimidine and its N4-acetyl metabolite in pigs. Baakman, M; Driessens, F; Mevius, DJ; Nouws, JF; Vellenga, L; Vree, TB, 1986) | 0.27 |
| " nonsmoking state, as measured by %ASMZ in serum six hours post-SMZ dosing or by %ASMZ in urine five to six hours post-SMZ dosing." | ( No effect of smoking on sulfamethazine acetylation. Cosgriff, JM; Miller, ME, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (50.00) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.55%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 21 (95.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||